Chinese Covid-19 vaccine developers are under a lot of pressure in the race to `get to the finish line`.

On November 23, pharmaceutical company AstraZeneca and Oxford University said their Covid-19 vaccine is 62-90% effective.

China’s Covid-19 vaccines entered late-stage testing in July, around the same time as the Pfizer and Moderna candidates.

Researchers need to wait for a certain number of infections before calculating the effectiveness and comparing the vaccine and placebo groups.

Peter Maybarduk, director of the nonprofit group Public Citizen in Washington, said: `China announced the distribution of Covid-19 vaccines globally but we need to know the details about it.`

Chinese authorities did not wait for the results of late-stage clinical trials.

In September, the UAE administered Chinese Covid-19 vaccine to medical staff.

At least one government is pausing approval of a Chinese vaccine due to lack of clinical evidence.

The Indonesian government is considering emergency licensing of China’s Covid-19 vaccine.

A medical worker is injected with the Covid-19 vaccine developed by Chinese drug manufacturer Sinovac Biotech as part of a clinical trial in Istanbul, October 9.

Sinovac’s late-stage trial is underway in Brazil.

Ms. Lukito said the BPOM agency could not know the Brazilian research data.

Chinese vaccine developers have to go to other countries to conduct testing because the Covid-19 epidemic is almost under China’s control.

Pierre A.Morgon, Senior Vice President in charge of international business at CanSino Biologic, the company that is collaborating with the Chinese military to develop vaccines, said AstraZeneca and Pfizer have an advantage because they have experienced research teams.

In early May, President Xi Jinping expected that China would play a big role in efforts to repel the pandemic in the world.

“If China wants to use vaccines as a diplomatic tool targeting low-income countries, it still has to

Opportunity for China

The global vaccine distribution program established by the World Health Organization and other international organizations may not be able to quickly provide vaccines to developing countries, and must wait until the end of next year.

Another potential advantage is the temperature at which Covid-19 vaccines are stored.

The head of PT Bio Farma, Indonesia’s state-owned vaccine manufacturer, said preserving vaccines at low temperatures is difficult when distributing.

Dicky Budiman, an Indonesian epidemiologist at Griffith University in Australia, said that even if Sinovac takes a long time to get trial results, Indonesia is still a potential market, because Sinovac’s vaccine is cheap and inexpensive.

`In the meantime, the biggest challenge right now is dealing with the pandemic,` Budiman said.